Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Drug-related morbidity and mortality: updating the cost-of-illness model.

Ernst FR, Grizzle AJ.

J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192-9.

PMID:
11297331
2.

Drug-related morbidity and mortality. A cost-of-illness model.

Johnson JA, Bootman JL.

Arch Intern Med. 1995 Oct 9;155(18):1949-56.

PMID:
7575048
3.

The health care cost of drug-related morbidity and mortality in nursing facilities.

Bootman JL, Harrison DL, Cox E.

Arch Intern Med. 1997 Oct 13;157(18):2089-96.

PMID:
9382665
4.

Costs of drug-related morbidity and mortality: enormous and growing rapidly.

Bates DW.

J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):156-7. No abstract available.

PMID:
11297325
5.

New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada.

Bentkover JD, Stewart EJ, Ignaszewski A, Lepage S, Liu P, Cooper J.

Int J Cardiol. 2003 Mar;88(1):33-41.

PMID:
12659982
6.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
7.

Economic cost of Guillain-Barré syndrome in the United States.

Frenzen PD.

Neurology. 2008 Jul 1;71(1):21-7. doi: 10.1212/01.wnl.0000316393.54258.d1.

PMID:
18591502
8.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association.

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
9.

Drug-related morbidity and mortality and the economic impact of pharmaceutical care.

Johnson JA, Bootman JL.

Am J Health Syst Pharm. 1997 Mar 1;54(5):554-8. No abstract available.

PMID:
9066865
10.

Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment.

Cunningham G, Dodd TR, Grant DJ, McMurdo ME, Richards RM.

Age Ageing. 1997 Sep;26(5):375-82.

PMID:
9351482
11.
12.

The incidence of drug-related problems as a cause of hospital admissions in children.

Easton KL, Parsons BJ, Starr M, Brien JE.

Med J Aust. 1998 Oct 5;169(7):356-9.

PMID:
9803246
13.

The economic burden of schizophrenia in the United States in 2002.

Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

J Clin Psychiatry. 2005 Sep;66(9):1122-9.

PMID:
16187769
14.

The economic burden of depression in the United States: how did it change between 1990 and 2000?

Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.

J Clin Psychiatry. 2003 Dec;64(12):1465-75.

PMID:
14728109
15.

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G.

Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.2165/00148365-200806040-00005.

PMID:
19382822
16.

The economic cost of illness revisited.

Cooper BS, Rice DP.

Soc Secur Bull. 1976 Feb;39(2):21-36.

PMID:
828774
17.

Economic costs of diabetes in the US in 2002.

Hogan P, Dall T, Nikolov P; American Diabetes Association.

Diabetes Care. 2003 Mar;26(3):917-32.

PMID:
12610059
18.

Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.

Delong LK, Culler SD, Saini SS, Beck LA, Chen SC.

Arch Dermatol. 2008 Jan;144(1):35-9. doi: 10.1001/archdermatol.2007.5.

PMID:
18209166
19.

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J.

Rheumatology (Oxford). 2004 Sep;43(9):1158-66. Epub 2004 Jun 29.

PMID:
15226514
20.

Cost of Gram-negative resistance.

Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, Sawyer RG.

Crit Care Med. 2007 Jan;35(1):89-95.

PMID:
17110877

Supplemental Content

Support Center